Ameriprise’s enGene Therapeutics ENGN Stock Holding History

Ameriprise’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-12,524	Closed	-$118K	–	3956
2024 Q2	$118K	Buy	+12,524	New	+$161K	﹤0.01%	3759

Other funds holding ENGN

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Ameriprise's ENGN Position: Q3 2024 in Review

Ameriprise sold out of enGene Therapeutics (ENGN) in Q3 2024, closing a stake of 12,524 shares — an estimated $118K sold.

Ameriprise first reported a position in ENGN in Q2 2024 and held it in 1 quarter. The position peaked at $118K in Q2 2024. 30 funds tracked by Wall St. Rank hold ENGN as of Q3 2024.

Ameriprise reported no remaining enGene Therapeutics position as of Q3 2024 after selling out during the quarter.
Ameriprise sold 12,524 enGene Therapeutics shares in Q3 2024, an estimated $118K.
Ameriprise first reported a position in enGene Therapeutics in Q2 2024 and held it in 1 quarter.
Ameriprise's enGene Therapeutics position peaked at $118K in Q2 2024.
30 funds tracked by Wall St. Rank held enGene Therapeutics as of Q3 2024.

Based on Ameriprise's 13F filing for Q3 2024, filed 14 Nov 2024.